

Daniel Truong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/955047/publications.pdf>

Version: 2024-02-01

43
papers

807
citations

1051969

10
h-index

1051228

16
g-index

44
all docs

44
docs citations

44
times ranked

649
citing authors

#	ARTICLE	IF	CITATIONS
1	The etiopathogenetic and pathophysiological spectrum of parkinsonism. Journal of the Neurological Sciences, 2022, 433, 120012.	0.3	8
2	Editorial: Tremors. Journal of the Neurological Sciences, 2022, 435, 120189.	0.3	1
3	Fist-Edge-Palm (FEP) test has a high sensitivity in differentiating dementia from normal cognition in Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 118060.	0.3	0
4	Prodromal Markers of Parkinson's Disease in Patients With Essential Tremor. Frontiers in Neurology, 2020, 11, 874.	1.1	9
5	The Critical Role of SIRT1 in Parkinson's Disease: Mechanism and Therapeutic Considerations. , 2020, 11, 1608.		67
6	Validating the Vietnamese version of wearing " Off 19 questionnaire for patients with Parkinson's disease. Clinical Parkinsonism & Related Disorders, 2019, 1, 37-40.	0.5	1
7	Eye movement abnormalities in movement disorders. Clinical Parkinsonism & Related Disorders, 2019, 1, 54-63.	0.5	17
8	Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study. Parkinsonism and Related Disorders, 2019, 64, 132-137.	1.1	37
9	Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 175-180.	1.1	37
10	Diffuse Lewy body disease. Journal of the Neurological Sciences, 2019, 399, 144-150.	0.3	6
11	Setting the record straight: The nosology of tardive syndromes. Parkinsonism and Related Disorders, 2019, 59, 146-150.	1.1	17
12	The nosology of tardive syndromes. Journal of the Neurological Sciences, 2018, 389, 10-16.	0.3	60
13	Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose Escalation Multicenter Study. Movement Disorders Clinical Practice, 2018, 5, 273-282.	0.8	42
14	Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. Journal of the Neurological Sciences, 2017, 376, 84-90.	0.3	30
15	A case report of multiple system atrophy treated with an Abelson tyrosine kinase inhibitor. Journal of the Neurological Sciences, 2017, 382, 53-54.	0.3	3
16	Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism and Related Disorders, 2010, 16, 316-323.	1.1	127
17	Pharmacology of botulinum toxin drugs. , 2009, , 13-22.		5
18	Developing the next generation of botulinum toxin drugs. , 2009, , 205-208.		0

#	ARTICLE	IF	CITATIONS
19	Botulinum toxin applications in ophthalmology. , 2009, , 77-84.		0
20	Efficacy and safety of purified botulinum toxin type A (Dysport®) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial. Parkinsonism and Related Disorders, 2008, 14, 407-414.	1.1	82
21	Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Movement Disorders, 2005, 20, 783-791.	2.2	234
22	Foreword “ Alan B. Scott. , 0, , xiii-xiv.		0
23	Cosmetic uses of botulinum toxins. , 0, , 133-142.		0
24	Treatment of stiff-person syndrome with botulinum toxin. , 0, , 189-194.		0
25	Hyperhidrosis. , 0, , 123-132.		2
26	Botulinum toxin in tic disorders and essential hand and head tremor. , 0, , 195-204.		2
27	Treatment of cervical dystonia. , 0, , 29-42.		6
28	Treatment of plantar fasciitis with botulinum toxin. , 0, , 185-188.		1
29	Botulinum toxin: history of clinical development. , 0, , 9-12.		0
30	The use of botulinum toxin in the management of headache disorders. , 0, , 175-184.		0
31	The pretherapeutic history of botulinum toxin. , 0, , 1-8.		1
32	Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes. , 0, , 85-92.		0
33	Spasticity. , 0, , 101-114.		2
34	Treatment of blepharospasm. , 0, , 49-52.		2
35	Botulinum toxin in urological disorders. , 0, , 153-160.		0
36	Immunological properties of botulinum toxins. , 0, , 23-28.		1

#	ARTICLE	IF	CITATIONS
37	Treatment of oromandibular dystonia. , 0, , 53-60.		3
38	Treatment of focal hand dystonia. , 0, , 61-76.		1
39	The use of botulinum toxin in otorhinolaryngology. , 0, , 93-100.		1
40	Botulinum toxin in the gastrointestinal tract. , 0, , 143-152.		0
41	Treatment of hemifacial spasm. , 0, , 43-48.		1
42	Use of botulinum toxin in musculoskeletal pain and arthritis. , 0, , 161-174.		0
43	The use of botulinum toxin in spastic infantile cerebral palsy. , 0, , 115-122.		0